[go: up one dir, main page]

WO2024194045A1 - Ensemble capuchon d'un dispositif d'administration de médicament - Google Patents

Ensemble capuchon d'un dispositif d'administration de médicament Download PDF

Info

Publication number
WO2024194045A1
WO2024194045A1 PCT/EP2024/056273 EP2024056273W WO2024194045A1 WO 2024194045 A1 WO2024194045 A1 WO 2024194045A1 EP 2024056273 W EP2024056273 W EP 2024056273W WO 2024194045 A1 WO2024194045 A1 WO 2024194045A1
Authority
WO
WIPO (PCT)
Prior art keywords
tubular body
delivery member
inner body
housing
syringe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/056273
Other languages
English (en)
Inventor
Oscar Alexandersson
Anders BOSTRÖM
Johan Zander
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHL Medical AG
Original Assignee
SHL Medical AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHL Medical AG filed Critical SHL Medical AG
Priority to CN202480013510.4A priority Critical patent/CN120731101A/zh
Publication of WO2024194045A1 publication Critical patent/WO2024194045A1/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3202—Devices for protection of the needle before use, e.g. caps
    • A61M5/3204—Needle cap remover, i.e. devices to dislodge protection cover from needle or needle hub, e.g. deshielding devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A61M2005/2418—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic comprising means for damping shocks on ampoule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A61M5/2033—Spring-loaded one-shot injectors with or without automatic needle insertion

Definitions

  • a cap assembly of a medicament delivery device is provided.
  • the present disclosure generally relates to a cap assembly of a medicament delivery device, and particularly to a cap assembly of a medicament delivery device comprising a tubular body and a lid movable relative to the tubular body.
  • Medicament delivery devices such as pen-type manual injectors or auto-injectors are generally known for the self-administration of a medicament by patients without formal medical training.
  • patients suffering from diabetes may require repeated injections of insulin, or patients may require regular injections of other types of medicaments, such as growth hormones.
  • the medicament delivery devices for self-administration comprise automatic functions so that even if users are without professional training or are in an emergency, the users can easily and properly use the medicament delivery devices.
  • Medicament delivery devices may comprise a cap.
  • Examples of medicament delivery devices, or drug delivery devices are disclosed in US 11 147932 B2, WO 2020/0699994 A1 , and US 2022/078987 AI .Even though many of the devices on the market, as well as the ones described above, have their respective advantages, there is still room for improvement.
  • distal direction refers to the direction pointing away from the dose delivery site during use of the medicament delivery device.
  • distal part/end refers to the part/end of the delivery device, or the parts/ends of the members thereof, which under use of the medicament delivery device is/are located furthest away from the dose delivery site.
  • proximal direction refers to the direction pointing towards the dose delivery site during use of the medicament delivery device.
  • proximal part/end this refers to the part/end of the delivery device, or the parts/ends of the members thereof, which under use of the medicament delivery device is/are located closest to the dose delivery site.
  • longitudinal refers to a direction extending from the proximal end to the distal end, typically along the device or components thereof in the direction of the longest extension of the device and/or component.
  • transverse refers to a direction generally perpendicular to the longitudinal direction.
  • circumference refers to a circumference or a circumferential direction relative to an axis, typically a central axis extending in the direction of the longest extension of the device and/or component.
  • radial refers to a direction extending radially relative to the axis
  • rotation refers to rotation relative to the axis.
  • a cap assembly of a medicament delivery device comprising a syringe having a barrel, a delivery member shield and a ramp shoulder extending between the barrel and the delivery member shield, the cap assembly comprising: a tubular body extending along a longitudinal axis between a proximal end and a distal end; a lid partially received within the tubular body.
  • the lid comprises a lid cover extending in a direction transverse to the longitudinal axis and an inner body extending from the lid cover towards the distal end of the tubular body.
  • the lid cover is movably attached to the proximal end of the tubular body and is immovably attached to the inner body.
  • the inner body comprises a radially flexible gripper configured to engage with the delivery member shield such that the delivery member shield can be removed from the barrel of the syringe by a proximal movement of the inner body relative to the barrel of the syringe.
  • the lid is axially movable relative to the tubular body in the direction of the longitudinal axis between a distal position and a proximal position.
  • a slot is arranged in a wall of the inner body and extending in the direction of the longitudinal axis from a distal end of the inner body to a proximal portion of the inner body such that the inner body is circumferentially deformable when the delivery member shield passes through the distal end of the inner body.
  • the inner body comprises a plurality of grippers arranged at the distal end of the inner body.
  • the lid is configured to be moved from the distal position to the proximal position by a resilient force of the gripper when the delivery member shield of the syringe is received in the inner body followed by inserting the delivery member shield of the syringe into the inner body to a position where the distal end of the delivery member shield is spaced apart from the gripper.
  • the lid is configured to be moved to the distal position relative to the tubular body before inserting the delivery member shield of the syringe into the inner body.
  • a distal end of the gripper is configured to be in contact with a proximal end of the delivery member shield of the syringe before the lid is moved to the distal position relative to the tubular body.
  • the lid cover comprises a proximally directed surface; and the tubular body comprises a distally directed surface.
  • the proximally directed surface of the lid cover is engaged with the distally directed surface of the tubular body when the lid is in the proximal position.
  • the lid cover comprises a distally directed surface; and the tubular body comprises a proximally directed surface.
  • the distally directed surface of the lid cover is engaged with the proximally directed surface of the tubular body when the lid is in the distal position.
  • the tubular body comprises a fixture configured to engage with a counter fixture of a housing of the medicament delivery device.
  • the lid is configured to be in the proximal position when the fixture is engaged with the counter fixture.
  • the tubular body is configured to be moved a first distance in the direction of the longitudinal axis relative to the housing of the medicament delivery device to detach the fixture from the counter fixture.
  • the lid is configured to be moved a second distance from the proximal position to the distal position in the direction of the longitudinal axis relative to the tubular body.
  • the second distance is greater than the first distance.
  • the distal end of the tubular body is radially flexible.
  • the distal end of the tubular housing comprises a curved surface configured to interact with a counter curved surface of a component of the medicament delivery device such that a rotation of the tubular housing around the longitudinal axis relative to the component of the medicament delivery device can be converted to an axial movement of the tubular housing in the direction of the longitudinal axis by the interaction between the curved surface and the counter curved surface.
  • the curved surface of the tubular housing is a distally directed surface.
  • the lid cover is movably attached to the proximal end of the tubular body via a snap-fit engagement.
  • the cap assembly is used in a medicament delivery device comprising a housing extending along the longitudinal axis between a proximal end and a distal end; and a syringe comprising a barrel, a delivery member shield and a ramp shoulder extending between the barrel and the delivery member shield; wherein the syringe is arranged within the housing.
  • the medicament delivery device comprises a delivery member guard radially arranged between the housing and the syringe.
  • the delivery member guard comprises a radially flexible arm adjacent to the delivery member shield of the syringe.
  • the radially flexible arm comprises a distally directed surface engaged with a proximally directed surface of the housing.
  • At least one of the distally directed surface of the flexible arm and the proximally directed surface of the housing is a ramp surface.
  • the delivery member guard has an axial opening arranged to receive the inner body, wherein the axial opening and an outer perimeter of the inner body have non-circular cross sectional shapes that mate to prevent rotation of the inner body relative to the delivery member guard, and wherein the tubular body is configured to rotate relative to the inner body when the tubular body is turned relative to the housing allowing the inner body to move linearly when the tubular body is moved in a cap removal direction by rotation.
  • the tubular body comprises a fixture configured to engage with a counter fixture of the housing, wherein the lid is configured to be in the proximal position when the fixture is engaged with the counter fixture, wherein the tubular body is configured to be moved a first distance in the direction of the longitudinal axis relative to the housing to detach the fixture from the counter fixture, wherein the lid is configured to be moved a second distance from the proximal position to the distal position in the direction of the longitudinal axis relative to the tubular body; and wherein the second distance is greater than the first distance.
  • the distal end of the tubular body is radially flexible.
  • the medicament delivery device comprises a single-chamber syringe.
  • the medicament delivery device comprises a multiple-chamber syringe.
  • the barrel of the syringe is configured to accommodate medicament to be delivered.
  • the syringe is made of glass material or plastic material.
  • the medicament delivery device is an injection device, an inhalation device, or a medical sprayer.
  • the medicament delivery device is an auto-injector.
  • the delivery member is an injection needle or a spray nozzle.
  • a medicament delivery device comprising: a housing, a delivery guard member movably arranged in the housing and rotationally locked relative to the housing, and a cap assembly comprising: a tubular body configured to be removably attached to the housing, and a lid having an inner body arranged radially inside of and concentrically with the tubular body, the inner body being configured to axially engage with the tubular body, the inner body having a gripper configured to engage with a delivery member shield provided on a syringe, wherein the tubular body and the housing are arranged to cooperate with each other by means of a respective cam surface, whereby, when the tubular body is attached to the housing, rotation of the tubular body relative to the housing causes axial movement of the tubular body relative to the housing in a cap removal direction, wherein the delivery member guard has an axial opening arranged to receive the inner body, wherein the axial opening and an outer perimeter of the inner body have non-circular cross sectional shapes that
  • the inner body comprises a fitting arm and the tubular body has a flange, and wherein the axial engagement between the tubular body and the inner body is provided by the fitting arm and the flange.
  • the lid is configured to move axially relative to the tubular body, from a distal position in which the fitting arm is axially spaced apart from the flange to a proximal position in which the fitting arm engages with the flange.
  • the axial opening has a radial slot
  • the inner body has a radial protrusion arranged to engage with the radial slot to prevent rotation of the inner body relative to the delivery member guard.
  • tubular body is configured to rotate freely relative to the inner body.
  • One embodiment comprises a syringe arranged in the housing, the syringe being provided with a delivery member, and a delivery member shield arranged on the delivery member.
  • the gripper engages with the delivery member shield.
  • the medicament delivery devices described herein can be used for the treatment and/or prophylaxis of one or more of many different types of disorders.
  • exemplary disorders include, but are not limited to: rheumatoid arthritis, inflammatory bowel diseases (e.g. Crohn’s disease and ulcerative colitis), hypercholesterolaemia, diabetes (e.g. type 2 diabetes), psoriasis, migraines, multiple sclerosis, anaemia, lupus, atopic dermatitis, asthma, nasal polyps, acute hypoglycaemia, obesity, anaphylaxis and allergies.
  • Exemplary types of medicaments that could be included in the medicament delivery devices described herein include, but are not limited to, small molecules, hormones, cytokines, blood products, antibodies, antibody-drug conjugates, bispecific antibodies, proteins, fusion proteins, peptibodies, polypeptides, pegylated proteins, protein fragments, protein analogues, protein variants, protein precursors, chimeric antigen receptor T cell therapies, cell or gene therapies, oncolytic viruses, or immunotherapies and/or protein derivatives.
  • Exemplary medicaments that could be included in the medicament delivery devices described herein include, but are not limited to (with non-limiting examples of relevant disorders in brackets): etanercept (rheumatoid arthritis, inflammatory bowel diseases (e.g.
  • evolocumab hypercholesterolaemia
  • exenatide type 2 diabetes
  • secukinumab psoriasis
  • erenumab mimerase
  • alirocumab rheumatoid arthritis
  • methotrexate amethopterin
  • tocilizumab rheumatoid arthritis
  • interferon beta-1 a multiple sclerosis
  • sumatriptan miraines
  • adalimumab rheumatoid arthritis
  • darbepoetin alfa anaemia
  • sarilumab rheumatoid arthritis
  • semaglutide type 2 diabetes, obesity
  • dupilumab atopic dermatitis, asthma, nasal polyps, allergies
  • glucagon glucagon
  • ipilimumab nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, cemiplimab, rituximab, trastuzumab, ado-trastuzumab emtansine, famtrastuzumab deruxtecan-nxki, pertuzumab, transtuzumab-pertuzumab, alemtuzumab, belantamab mafodotin-blmf, bevacizumab, blinatumomab, brentuximab vedotin, cetuximab, daratumumab, elotuzumab, gemtuzumab ozogamicin, 90-Yttrium-ibritumomab tiuxetan, isatuximab,
  • compositions including, but not limited to, any drug described herein are also contemplated for use in the medicament delivery devices described herein, for example, pharmaceutical formulations comprising a drug as listed herein (or a pharmaceutically acceptable salt of the drug) and a pharmaceutically acceptable carrier.
  • pharmaceutical formulations comprising a drug as listed herein (or a pharmaceutically acceptable salt of the drug) may include one or more other active ingredients, or may be the only active ingredient present.
  • Exemplary medicaments that could be included in the medicament delivery devices described herein include, but are not limited to, an immuno-oncology or biooncology medications such as immune checkpoints, cytokines, chemokines, clusters of differentiation, interleukins, integrins, growth factors, enzymes, signaling proteins, pro-apoptotic proteins, anti-apoptotic proteins, T-cell receptors, B-cell receptors, or costimulatory proteins.
  • an immuno-oncology or biooncology medications such as immune checkpoints, cytokines, chemokines, clusters of differentiation, interleukins, integrins, growth factors, enzymes, signaling proteins, pro-apoptotic proteins, anti-apoptotic proteins, T-cell receptors, B-cell receptors, or costimulatory proteins.
  • Exemplary medicaments that could be included in the medicament delivery devices described herein include, but are not limited to, those exhibiting a proposed mechanism of action, such as HER-2 receptor modulators, interleukin modulators, interferon modulators, CD38 modulators, CD22 modulators, CCR4 modulators, VEGF modulators, EGFR modulators, CD79b modulators, Trop-2 modulators, CD52 modulators, BCMA modulators, PDGFRA modulators, SLAMF7 modulators, PD- 1/PD-L1 inhibitors/modulators, B-lymphocyte antigen CD19 inhibitors, B-lymphocyte antigen CD20 modulators, CD3 modulators, CTLA-4 inhibitors, TIM-3 modulators, VISTA modulators, INDO inhibitors, LAG3 (CD223) antagonists, CD276 antigen modulators, CD47 antagonists, CD30 modulators, CD73 modulators, CD66 modulators, CDw137 agonists, CD158 modulators, CD27 modulators, CD58 modulators, CD80 modulators, CD33 modul
  • Exemplary medicaments that could be included in the medicament delivery devices described herein include, but are not limited to, a multi-medication treatment regimen such as AC, Dose-Dense AC, TCH, GT, EC, TAC, TC, TCHP, CMF, FOLFOX, mFOLFOX6, mFOLFOX7, FOLFCIS, CapeOx, FLOT, DCF, FOLFIRI, FOLFIRINOX, FOLFOXIRI, IROX, CHOP, R-CHOP, RCHOP-21 , Mini-CHOP, Maxi- CHOP, VR-CAP, Dose-Dense CHOP, EPOCH, Dose-Adjusted EPOCH, R-EPOCH, CODOX-M, IVAC, HyperCVAD, R-HyperCVAD, SC-EPOCH-RR, DHAP, ESHAP, GDP, ICE, MINE, CEPP, CDOP, GemOx, CEOP, CEPP, CHOEP, CHP, GCVP,
  • Exemplary medicaments that could be included in the medicament delivery devices described herein include, but are not limited to, those used for chemotherapy, such as an alkylating agent, plant alkaloid, antitumor antibiotic, antimetabolite, or topoisomerase inhibitor, enzyme, retinoid, or corticosteroid.
  • chemotherapy such as an alkylating agent, plant alkaloid, antitumor antibiotic, antimetabolite, or topoisomerase inhibitor, enzyme, retinoid, or corticosteroid.
  • Exemplary chemotherapy medicaments include, by way of example but not limitation, 5- fluorouracil, cisplatin, carboplatin, oxaliplatin, doxorubicin, daunorubicin, idarubicin, epirubicin, paclitaxel, docetaxel, cyclophosphamide, ifosfamide, azacitidine, decitabine, bendamustine, bleomycin, bortezomib, busulfan, cabazitaxel, carmustine, cladribine, cytarabine, dacarbazine, etoposide, fludarabine, gemcitabine, irinotecan, leucovorin, melphalan, methotrexate, pemetrexed, mitomycin, mitoxantrone, temsirolimus, topotecan, valrubicin, vincristine, vinblastine, or vinorelbine.
  • Fig. 1 schematically shows a perspective view of a cap assembly of the invention and a housing of a medicament delivery device
  • Fig. 2 schematically shows a perspective view of the cap assembly of Fig. 1 and a syringe of the medicament delivery device;
  • Fig. 3 schematically shows a cross-section view of the cap assembly of Fig. 1 ;
  • Figs 4-5 schematically show cross-section views of one embodiment of the cap assembly of Fig. 1 with the medicament delivery device
  • Figs 6-7 schematically show perspective views of another embodiment of the cap assembly of Fig. 1 with the medicament delivery device;
  • Figs 8A-8E schematically show cress-section views of an operation sequence of the medicament delivery device of the invention
  • Fig. 9 schematically shows a perspective view of an embodiment of the medicament delivery device of the invention.
  • Figs 9-10 schematically show perspective views of an embodiment of the medicament delivery device of the invention with indication mechanism arrangement
  • Fig. 11 schematically shows a cross-section view of an embodiment of the medicament delivery device of the invention with indication mechanism arrangement
  • Fig. 12 schematically shows a perspective view of an embodiment of the medicament delivery device of the invention with indication mechanism arrangement
  • Figs 13-14 schematically show a perspective view and a cross-section view of the cap assembly in another example
  • Figs 15-18 schematically show perspectives view of another embodiment of the medicament delivery device of the invention with a delivery member guard lockout mechanism arrangement
  • Fig. 19 schematically shows an exploded view of a medicament delivery device comprising the cap assembly of the invention without the syringe;
  • Fig. 20 schematically shows a perspective view of a powerpack of the medicament delivery device
  • Fig. 21 is a perspective view of a proximal portion of another example of a medicament delivery device
  • Fig. 22 are perspective views of an example of an inner body to the left, and a delivery member guard to the right;
  • Fig. 23 is a perspective view of the proximal portion with a tubular body of a lid assembly removed;
  • Fig. 24 is a longitudinal section of the a proximal portion of the medicament delivery device in Fig. 21 ;
  • Fig. 25 is a cross-section of the medicament delivery device in Fig. 21 , along lines A-A;
  • Fig. 26 illustrates when the cap assembly is removed from the housing
  • Fig. 27 is a cross section of an example of a medicament delivery device which allows rotation of the syringe inside the housing, before cap assembly removal;
  • Fig. 28 shows the medicament delivery device in Fig. 27 after cap assembly removal.
  • Figs 1-14 illustrate examples of a cap assembly
  • a medicament delivery device comprises a cap assembly.
  • the medicament delivery device comprises a syringe 4 having a barrel 40, a delivery member shield 43 and a ramp shoulder 40a extending between the barrel 40 and the delivery member shield 43.
  • the ramp shoulder 40a is inclined from the barrel to the delivery shield 43 in a direction of a longitudinal axis L.
  • a proximally directed ramp surface is formed, as shown in Fig. 2 and Fig. 4.
  • the deliver member shield 43 is configured to seal a delivery member 44.
  • the delivery member is a needle.
  • the delivery member shield can be a flexible needle shield or a flexible needle shield positioned within a rigid needle shield.
  • the flexible needle shield is usually made of a resilient material, e.g., rubber.
  • the rigid needle shield is usually made of hard plastic.
  • the cap assembly comprises a user-accessible part 2 configured to be gripped by a user of the medicament delivery device for removing the cap assembly from a housing 1 of the medicament delivery device.
  • the user-accessible part comprises a tubular body 20 extending along the longitudinal axis L between a proximal end and a distal end.
  • the tubular body 20 comprises a gripping feature 24 to facilitate the grip of the user.
  • the gripping feature is multiple recesses.
  • the cap assembly comprises a lid 3 partially received within the tubular body 20, as shown in Fig. 3.
  • the lid 3 comprises a lid cover 31 extending in a direction transverse to the longitudinal axis L and an inner body 30 extending from the lid cover 31 towards the distal end of the tubular body 20.
  • the lid cover 31 is movably attached to the proximal end of the tubular body 20 and is immovably attached to the inner body 30.
  • the lid cover 31 is an integral part of the inner body 30.
  • the lid cover and the inner body can be two components attached to one another, e.g., are screwed together or clamped together.
  • the lid cover 31 is movably attached to the proximal end of the tubular body 20 via a snap-fit engagement, as shown in Fig 3.
  • the lid cover 31 comprises a fitting arm 32 comprising a hook.
  • the tubular body 20 comprises a ledge 20a being hooked by the hook of the fitting arm 32.
  • an axial length X2 of the fitting arm defines an axial movable distance of the lid cover 31 relative to the tubular body 20, as shown in Fig. 3.
  • the lid cover 31 comprises a protrusion and a groove might be arranged in a wall of the tubular body.
  • the protrusion is movable within the groove.
  • An axial length of the groove defines an axial movable distance of the lid cover relative to the tubular body.
  • the tubular body 20 comprises a proximal opening 23, in this example, the inner body 30 of the lid 3 is positioned through the proximal opening 23; and the lid cover 31 covers the proximal opening 23 when the lid 3 is attached to the tubular body 20.
  • the inner body 30 comprises a radially flexible gripper 33 configured to engage with the delivery member shield 43 such that the delivery member shield 43 can be removed from the barrel of the syringe 4 by a proximal movement of the inner body 30 relative to the barrel of the syringe 4.
  • the lid cover 31 is movably attached to the tubular body 20, the lid 3 is axially movable relative to the tubular body 20 in the direction of the longitudinal axis L between a distal position and a proximal position.
  • the cap assembly can be used for improving the manufacture of the medicament delivery device. In particular, improving the compatibility for variations in the length of syringes/delivery member shields.
  • a distal end of the gripper 33 can be used to be a reference point for inserting the syringe 4 with the delivery member shield 43 into the inner body 30.
  • the distal end of the gripper 33 is configured to be in contact with a proximal end of the delivery member shield 43 of the syringe 4.
  • the lid 3 is configured to be moved to the distal position relative to the tubular body 20 before inserting the delivery member shield of the syringe into the inner body 30.
  • the lid 3 is in the distal position when the proximal end of the delivery member shield is in contact with the distal end of the gripper 33.
  • the delivery member shield 43 is configured to be inserted into the inner body 30 to a position where the distal end of the delivery member shield 43 is spaced apart from the gripper 33, as shown in Fig 6.
  • the gripper 33 is deflected outwardly from the longitudinal axis L by the ramp shoulder 40a of the syringe 4 when the delivery member shield 43 is reached this position.
  • the gripper 33 is radially flexible and the lid 3 is axially movable relative to the tubular body 20, once a support force, e.g., from the assembling tool, is removed from the lid 3, the lid 3 is moved from the distal position to the proximal position by a resilient force of the gripper 33, as shown in Fig. 7. Therefore, the gripper 33 is automatically positioned to engage with the distal end of the delivery member shield 43.
  • the cap assembly is used with a syringe collar 8 that is configured to be positioned adjacent to a proximal end of a flange 41 of the syringe 4.
  • the syringe collar 8 is configured to connect the syringe to the housing.
  • the gripper 33 when the syringe is inserted into the inner body 30, the syringe is configured to be inserted until the flange 41 is in contact with the syringe collar 8.
  • the gripper 33 forces the syringe 4 to move in the distal direction relative to the inner body 30 so that the gripper 33 can flex radially inward to engage the distal end of the delivery member shield 43.
  • the insertion force at the distal end of the syringe can be removed after the support force is removed from the lid 3. Therefore, the syringe 4 will only be moved in the distal direction relative to the inner body 30 when the movable distance of the lid 3 relative to the tubular body 20 is not enough to compensate for the syringe length tolerance.
  • the cap assembly and the syringe collar can be compatible for a greater variation in the length of syringes/delivery member shields.
  • the lid 3 does not need to be axially movable relative to the tubular body 20 to provide the manufacturing benefit.
  • the lid 3’ can be an integral part of the tubular body 20’ as shown in Figs 13-14.
  • the slot 30a is arranged in a wall of the inner body 30 and extends in the direction of the longitudinal axis L from a distal end of the inner body 30 to a proximal portion of the inner body 30 such that the inner body 30 is circumferentially deformable when the delivery member shield 43 passes through the distal end of the inner body 30.
  • the gripper 33 can be formed at the distal end of the inner body 30.
  • the gripper 33 is a gripping arm extending from the distal end of the inner body towards the distal end of the tubular body, the inner body 30 does not need to be arranged with the slot 30a.
  • the slot is extending beyond 50% of the total axial length of the inner body 30, as shown in Fig. 1 .
  • the slot is extending about 30-50% of the total axial length of the inner body 30.
  • the inner body 30 comprises a plurality of grippers 33 arranged at the distal end of the inner body 30.
  • the lid cover 31 comprises a proximally directed surface 32a.
  • the tubular body 20 comprises a distally directed surface, and the proximally directed surface of the lid cover 31 is engaged with the distally directed surface of the tubular body 20 when the lid 3 is in the proximal position.
  • the lid cover 31 comprises the fitting arm 32
  • the hook of the fitting arm 32 comprises the proximally directed surface 32a
  • the ledge 20a of the tubular body 20 comprises the distally directed surface, as shown in Fig. 3.
  • the lid cover 31 comprises a distally directed surface 31a; and the tubular body 20 comprises a proximally directed surface.
  • the distally directed surface of the lid cover 31 is engaged with the proximally directed surface of the tubular body 20 when the lid 3 is in the distal position.
  • the tubular body 20 comprises the ledge 20a
  • the ledge 20a of the tubular body 20 comprises the proximally directed surface.
  • the tubular body 20 comprises a fixture 21 configured to engage with a counter fixture 12 of the housing 1 of the medicament delivery device, as shown in Fig. 1 .
  • the lid 3 is configured to be in the proximal position when the fixture 21 is engaged with the counter fixture 12.
  • the tubular body 20 is configured to be moved a first distance X1 in the direction of the longitudinal axis L relative to the housing 1 of the medicament delivery device to detach the fixture 21 from the counter fixture 12.
  • the lid 3 is configured to be moved a second distance X2 from the proximal position to the distal position in the direction of the longitudinal axis L relative to the tubular body 20, as shown in Fig. 3.
  • the second distance X2 is greater than the first distance X1 , as shown in Fig. 4.
  • the fixture 21 and the counter fixture 12 can prevent the cap assembly from accidentally detach from the housing 1 of the medicament delivery device. However, it might also increase the resistance for the user to remove the cap assembly when the user plans to carry out a medicament delivery operation. In particular, friction between the delivery member shield and the delivery member and/or the syringe might be high, it might be difficult for the user to overcome the friction and the engagement between the fixture 21 and the counter fixture 12 at the same time.
  • the second distance X2 is greater than the first distance X1
  • the user only needs to overcome the engagement between the fixture 21 and the counter fixture 12 first (moves the tubular body 20 the first distance X1), then overcome the friction later (moves the tubular body further to engage with the lid 3, and starts to move the lid 3 and detaches the delivery member shield 43).
  • the distal end of the tubular body 20 is radially flexible, as shown in Fig. 5.
  • the fixture 21 is a cut-out and the counter fixture is a protrusion 12, as shown in Fig. 1.
  • the distal end of the tubular housing 20 comprises a curved surface 22 configured to interact with a counter curved surface of a component of the medicament delivery device such that a rotation of the tubular housing 20 around the longitudinal axis relative to the component of the medicament delivery device can be converted to an axial movement of the tubular housing 20 in the direction of the longitudinal axis L by the interaction between the curved surface 22 and the counter curved surface, as shown in Fig. 1.
  • the curved surface 22 of the tubular housing 20 is a distally directed surface.
  • the cap assembly is configured to be used with the medicament delivery device comprising the housing 1 extending along the longitudinal axis L between a proximal end and a distal end; and the syringe 4 comprising the barrel 40, the delivery member shield 43 and the ramp shoulder 40a extending between the barrel 40 and the delivery member shield 43.
  • the syringe 4 is arranged within the housing 1 .
  • the syringe 4 is axially immovable relative to the housing 1.
  • the syringe 4 is engaged to the housing via the syringe collar 8 adjacent to a flange 41 of the syringe 4, as shown in Figs 8A-8E.
  • the syringe collar 8 is attached to the housing 1 .
  • the medicament delivery device comprises a delivery member guard 5 radially arranged between the housing 1 and the syringe 4.
  • the delivery member guard 5 comprises a radially flexible arm 51 adjacent to the delivery member shield 43 of the syringe 4.
  • the radially flexible arm 51 comprises a distally directed surface 51a engaged with a proximally directed surface 10a of the housing 1.
  • at least one of the distally directed surface 51a of the flexible arm 51 and the proximally directed surface 10a of the housing 1 is a ramp surface.
  • the distally directed surface 51a of the flexible arm 51 is a ramp surface.
  • the delivery member guard 5 cannot be moved in the distal direction relative to the housing 1 as the distally directed surface 51a of the flexible arm 51 is abutted by the proximally directed surface 10a of the housing 1 .
  • the flexible arm 51 can flex radially inward, thus, the distally directed surface 51a of the flexible arm 51 can be disengaged from the proximally directed surface 10a of the housing 1 to allow the delivery member guard 5 to be moved in the distal direction relative to the housing 1 .
  • the distal movement of the delivery member guard 5 is configured to trigger the medicament delivery operation.
  • the medicament delivery device comprises a plunger rod 6 positioned within the housing 1 , and a plunger rod spring 63 configured to move the plunger rod 6 into the syringe to expel the medicament.
  • the plunger rod spring 63 is a compression spring.
  • the plunger rod spring 63 is preferably positioned within the plunger rod 6.
  • the medicament delivery device comprises a guide rod 13 configured to be positioned within the plunger rod spring 63 to avoid the plunger rod spring 63 from buckling.
  • the guide rod 13 can be an integral part of the housing 1 or a component that is attached to the housing 1 .
  • the delivery member guard 5 comprises a tubular section 50 surrounding the delivery member 44.
  • the delivery member guard 5 is biased in the proximal direction relative to the housing 1 by a delivery member guard spring 52.
  • the distal movement of the delivery member guard 5 is configured to release the plunger rod 6 from being operably engaged to the housing 1 , thus, the medicament delivery operation is started once the plunger rod 6 is released.
  • the medicament delivery device comprises an actuator 9 attached to the housing 1 via an actuator fixture 91 , e.g., snap fit.
  • the actuator 9 comprises a tubular-shaped body.
  • the actuator 9 comprises a flexible arm 93 having a distally directed surface configured to releasably engage with a proximally directed surface of the plunger rod 6.
  • a recess/cut-out 64 is arranged in a wall of the plunger rod 6, as shown in Figs 8B-C.
  • the proximally directed surface of the plunger rod 6 is defined by the edge of the recess/cut-out 64.
  • the actuator 9 comprises a flexible arm 94 extending in the proximal direction towards the syringe flange 41 .
  • the actuator 9 is configured to be in contact with the distal end of the syringe flange 41 , as shown in Fig. 12, Fig. 15, and Figs 17-18.
  • the medicament delivery device comprises an actuator sleeve 7; 7’
  • the delivery member guard spring 52 is positioned between the actuator sleeve 7; 7’ and the housing 1 .
  • the actuator sleeve 7; 7’ initially surrounds the flexible arm 93 of the actuator 9.
  • the distally directed surface of the flexible arm 93 of the actuator 9 is pushed towards the plunger rod 6 and therefore engage with the proximally directed surface of the plunger rod 6. Therefore, the plunger rod 6 is operably engaged with the housing 1 .
  • the delivery member guard 5 comprises a distally directed surface 53 configured to engage with a proximally directed surface 71 ; 71 ’ of the actuator sleeve 7; 7’.
  • the distal movement of the delivery member guard 5 moves the actuator sleeve 7 away from the flexible arm 93 of the actuator 9.
  • the flexible arm 93 can flex radially outwards from the plunger rod 6. Therefore, the distally directed surface of the flexible arm 93 of the actuator 9 disengages from the proximally directed surface of the plunger rod 6 and the plunger rod 6 is released from the housing 1 , as shown in Figs 8B-D.
  • the delivery member guard spring 52 biases the actuator sleeve 7; 7’ and the delivery member guard 5 in the proximal direction relative to the housing 1 .
  • the medicament delivery device comprises a locking ring.
  • the actuator sleeve is configured to snap fit to the locking ring when the actuator sleeve is moved distally by the delivery member guard.
  • the locking ring is configured to move past a ledge of the actuator.
  • the distal end of the actuator sleeve 7 comprises a locking arm 72 configured to snap fit to a recess of the actuator 9 when the actuator sleeve 7 and the delivery member guard 5 are biased in the proximal direction relative to the housing 1 .
  • the delivery member guard 5 is prevented from being moved in the distal direction relative to the housing 1 , as shown in Fig. 9.
  • the locking arm 72’ is configured to snap over a ledge 95 extending from the actuator 9, as shown in Fig. 16.
  • the actuator sleeve 7’ is positioned in a distal position before use, and the actuator sleeve 7’ is moved, by the delivery member guard spring 52, into a proximal position after the medicament delivery operation is completed and the delivery member guard 5 is lifted from the medicament delivery site. Therefore, when the user lifts the medicament delivery device from the medicament delivery site, the delivery member guard spring 52 biases the actuator sleeve 7’ in the proximal direction relative to the housing 1 from the distal position to the proximal position.
  • the locking arm 72’ of the actuator sleeve 7’ is moved past the ledge 95 when the actuator sleeve 7’ is moved from the distal position to the proximal position.
  • the actuator 9 and the plunger rod 6 are configured to releasbly hold the actuator sleeve 7’ in the distal position before use of the medicament delivery device.
  • the actuator sleeve 7’ comprises a ledge 74’ extending from an inner surface of the actuator sleeve 7’.
  • the ledge 74’ comprises a proximally directed surface 74a’; and the flexible arm 93’ of the actuator 9 comprises a distally directed surface 93a’.
  • the proximally directed surface 74a’ of the ledge 74’ of the actuator sleeve 7’ is engaged with the distally directed surface 93a’ of the actuator 9.
  • the actuator sleeve T is blocked from moving in the proximal direction relative to the housing 1.
  • the flexible arm 93’ of the actuator 9 can flex radially inward, as shown in Fig. 17.
  • the flexible arm is designed to accumulate tension force when being flexed radially outward, thus, once the plunger rod 6 is moved away from the inner surface of the flexible arm of the actuator, the flexible arm 93’ flexes radially inward towards the longitudinal axis L.
  • one of the distally directed surface 93a’ of the flexible arm 93’ of the actuator 9 and the proximally directed surface 74a’ of the ledge 74’ of the actuator sleeve 7’ is a chamfered surface, thus, once the plunger rod 6 is no longer blocking the flexible arm 93’ of the actuator 9 from flexing radially inward towards the longitudinal axis L, when the delivery member guard spring 52 biases the actuator sleeve 7’ in the proximal direction relative to the housing 1 , the flexible arm 93’ of the actuator 9 is pressed radially inward by the ledge 74’ of the actuator sleeve 7’.
  • the actuator sleeve 7’ can move into its proximal position.
  • the plunger rod 6 is configured to be moved away from the flexible arm 93’ of the actuator 9 when the plunger rod 6 reaches to its end position, e.g., the medicament delivery operation is ended.
  • the plunger rod can be designed to be moved away from the flexible arm of the actuator once the plunger rod is released to move in the proximal direction.
  • the delivery member guard and the actuator sleeve are immovably attached to one another in the direction of the longitudinal axis L, e.g., the delivery member guard is snap fitted to the actuator sleeve.
  • the delivery member guard is always immovably attached to one another.
  • the delivery member guard is only immovably attached to the actuator sleeve when the actuator sleeve is moved into its proximal position.
  • the delivery member guard is configured to further protrude from the proximal end of the housing after medicament delivery operation as the actuator sleeve is moved from the distal position to the proximal position.
  • a used indication can be provided to the user of the medicament delivery device.
  • a color code and/or a mark can be provided on a section of the delivery guard that is hidden within the housing before the medicament delivery device is used and protrudes from the housing after the medicament delivery is used.
  • the actuator sleeve is spaced apart from the delivery member guard when the actuator sleeve is in the distal position.
  • the delivery member guard moves a predetermined distance to be in contact with the proximal end of the actuator sleeve.
  • the distally directed surface 53 of the delivery member guard 5 engages with the proximally directed surface 71 of the actuator sleeve 7; 7’ such that the distal movement of the delivery member guard 5 moves the actuator sleeve 7; 7’ away from the flexible arm 93 of the actuator 9 to release the plunger rod 6 for expelling the medicament contained within the medicament delivery device.
  • the actuator sleeve 7’ comprises a snap arm 73’ configured to snap into an opening 54 of the delivery member guard 5, as shown in Figs 16-17 when the actuator sleeve 7’ is moved from its distal position to the proximal position.
  • the predetermined distance is between 0.5mm to 5mm, preferably, is 2mm. However, other predetermined distance can be set depending on the design.
  • the delivery member guard is configured to be pushed towards the actuator sleeve to snap fit with the actuator sleeve when the delivery member guard is initially pushed towards the distal direction relative to the housing.
  • the plunger rod 6 and the flexible arm 93’ of the actuator 9 are configured to hold the delivery member guard 5 in a retracted position where the delivery member is not fully surrounded by the delivery member guard.
  • the distally directed surface 93a’ of the flexible arm 93’ of the actuator 9 is configured to block the actuator sleeve 7 from moving in the proximal direction by engaging with a proximal end of the actuator sleeve 7’ until the plunger rod 6 is moved away from the flexible arm 93’ such that the flexible arm 93’ can flex radially inward towards the longitudinal axis L by either the actuator sleeve 7’ or the accumulated tension force of the flexible arm, as mentioned above.
  • the actuator sleeve 7’ can move in the proximal direction.
  • the delivery member guard 5 will be prevented from moving proximally relative to the housing 1 until the plunger rod 6 is moved away from the flexible arm 93’.
  • the medicament delivery device can provide an indication, preferably, audible and/or tactile indication to the user.
  • the indication can be medicament delivery started indication, end indication, and/or progress indication.
  • the indication is provided by an indication arm 92; 92’; 92” extending from the actuator 9.
  • the indication arm 92; 92” points to the distal end of the housing 1 , as shown in Fig. 11 .
  • the indication arm 92' points to the proximal end of the housing 1 , as shown in Fig. 10.
  • a counter indication protrusion 61 extending from the plunger rod 6, as shown in Figs 10-11 .
  • the indication is generated when the medicament delivery is close to the end, e.g., only one or two drops left.
  • the user might miss a single end click sound, thus, in this example, preferably, the user will hear 2-8 clicks, preferably, 4-8 clicks, when the medicament delivery is close to the end, and the user will be instructed to remove the medicament delivery device once the click sound/vibration is over.
  • the multiple-end- clicks design can make sure the users hold the medicament delivery device long enough to receive a full dose.
  • the counter indication protrusion 61 can be a set of rachet teeth, as shown in Fig. 11 and Fig. 15; alternatively, the counter indication protrusion 61 can be a set of discrete teeth, as shown in Fig. 10.
  • the set of discrete teeth are asymmetrically arranged relative to the plunger rod.
  • one side of the plunger rod can be arranged with a first tooth and a second tooth; and the other side of the plunger rod can be arranged with a third tooth and a fourth tooth.
  • the third tooth and the fourth tooth are both offset relative to the first tooth and the second tooth circumferentially and axially.
  • the indication arm extends from the plunger rod and the indication protrusion extends from the actuator.
  • the actuator comprises two indication arms being symmetrical to the longitudinal axis L.
  • the plunger rod 6 comprises multiple counter indication protrusions being asymmetrical to the plunger rod 6.
  • the indication is a progress indication configured to indicate to the user the progress of the medicament delivery operation.
  • the counter indication protrusion 61 can be a row of teeth, as shown in Fig. 11 .
  • Fig. 19 shows another example of a medicament delivery device comprising the cap assembly as mentioned above.
  • the housing 1’ comprises a main body 10’ and a rear cap 14’.
  • the main body 10’ is configured to accommodate the medicament container, e.g., the syringe 4.
  • the actuator 9 is configured to be attached to the housing 1 ’ via the rear cap 14’.
  • the actuator fixture feature 91 is configured to snap fit into an opening 14a of the rear cap 14’.
  • the delivery member guard spring 52 abuts at a proximal edge 14b of the rear cap 14’ at one end and abuts at a distally directed surface 75a’ of the actuator sleeve 7’.
  • the plunger rod 6, the actuator 9, the actuator sleeve 7’, the delivery member guard spring 52, the rear cap 14’, and the plunger rod spring 63 form a powerpack of the medicament delivery device, as shown in Fig. 20.
  • the powerpack is configured to be assembled as one unit.
  • the main body 10' of the housing 1 , the delivery member guard 5, the cap assembly, and the syringe collar 8 form a front sub-assembly.
  • the front subassembly is configured to be assembled as one unit.
  • the medicament delivery device is assembly with the following steps in the following orders:
  • the rear cap 14’ snap fits into the main body 10’ of the housing 1.
  • the above-mentioned features of the medicament delivery device e.g., the mechanism to prevent the distal movement of the delivery member guard after use of the medicament delivery device, the indication mechanism, and the mechanism to release the plunger rod for delivering medicament, can be used with the syringe 4 as disclosed and a cartridge, e.g., a delivery member is not initially attached to a container containing medicament.
  • Fig. 21 shows another example of a medicament delivery device.
  • the exemplified medicament delivery device comprises the housing 1 , and a lid assembly.
  • the lid assembly comprises a tubular body 20”.
  • the tubular body 20 has a curved surface 22
  • the housing 1 has a counter curved surface 11”.
  • the curved surface 22” and the counter curved surface 11” are cam surfaces configured to cooperate with each other.
  • the cam surfaces cooperate and cause axial movement of the tubular body 20” relative to the housing 1 in a cap removal direction also referred to as the proximal direction herein, shown by the arrow 100.
  • tubular body 20 may have a fixture and the housing 1 may have a counter fixture, which engage with each other to maintain the cap assembly in position relative to the housing 1 .
  • Fig. 22 shows a proximal portion of the medicament delivery device of Fig. 21 with the tubular body 20” removed.
  • the medicament delivery device comprises a delivery member guard 5” slidably arranged in the housing 1 .
  • the delivery member guard 5” is thus axially movable relative to the housing 1 .
  • the delivery member guard 5” is rotationally locked relative to the housing 1 .
  • the delivery member guard 5” is biased in the proximal direction. When the delivery member guard 5” is pushed into the housing 1 , a medicament delivery operation is triggered, as previously described herein.
  • the lid 3 comprises an inner body 30”.
  • the inner body 30” is arranged concentrically with the tubular body 20”.
  • the inner body 30” is arranged radially inwards of the tubular body 20”.
  • the inner body 30” is configured to engage axially with the tubular body 20” such that when the tubular body 20” is turned relative to the housing 1 and moved in the cap removal direction, the inner body 30” is moved axially in the cap removal direction together with the tubular body 20”.
  • the tubular body 20” may have an inner surface provided with a radially inwardly extending flange, or ledge, 20a”, shown in Fig.
  • the inner body 30 may comprise a fitting arm 32” which engage with the flange 20a” when the tubular body 20” is moved in the cap removal direction.
  • a distally directed surfaces of the flange 20a” bears against a proximally directed surface of the fitting arm 32”, for example.
  • the axial play may facilitate assembly of the syringe with the front sub-assembly of the medicament delivery device, for example in view of syringe size variations, as has previously been described.
  • the tubular body 20” and the inner body 30” may thus be arranged to move axially relative to each other, corresponding to the size of the axial play.
  • FIG. 23 perspective views of the inner body 30” and the delivery member guard 5” are shown.
  • the inner body 30 has an axial section with an outer perimeter that has a noncircular cross-section.
  • the inner body 30” may for example have one or more radial protrusions 102, which extend radially outwards along the axial section.
  • the inner body 30” may generally have a tubular outer surface and the radial protrusions 102 may be provided on the outer surface of the inner body 30”, thus making the outer perimeter non-circular along the axial section.
  • the inner body 30 comprises one or more grippers 33” which extend radially inwards.
  • Each gripper 33” is radially flexible and configured to engage with a distal end of a delivery member shield.
  • the one or more grippers 33” may be provided at a distal end of the inner body 30”.
  • the delivery member guard 5 has a central axial opening 104.
  • the axial opening 104 has a non-circular cross-sectional shape.
  • the axial opening 104 is configured to receive the inner body 30”.
  • the non-circular cross-sectional shape of the axial opening 104 is designed to mate with the outer perimeter of the inner body 30” provided with the one or more radial protrusions 102.
  • the inner body 30” is thus configured to engage with the delivery member guard 5” by this mating.
  • the axial opening 104 may be provided with one or more radial slots 106.
  • Each radial protrusion 102 is arranged to be received by a respective radial slot 106.
  • each radial protrusion 102 is arranged in a respective radial slot 106.
  • the delivery member guard 5 also comprises distally directed legs 107 between which the barrel of the syringe may be received.
  • the syringe flange may also be arranged between the legs 107.
  • the syringe flange may have a rotationally non- symmetric shape, which if the syringe would be rotated during cap assembly removal, would cause the syringe flange to strike the inner surface of the legs 107.
  • Fig. 24 shows a longitudinal section of the medicament delivery device when the lid assembly is assembled with the housing 1 .
  • the delivery member shield 43 is arranged around the delivery member, here exemplified by a needle. Each gripper 33” engages with a distal end of the delivery member shield 43.
  • Fig. 25 shows a cross-section along lines A-A in Fig. 24.
  • Each radial protrusion 102 is arranged in a respective radial slot 106 of the delivery member guard 5”.
  • the inner body 30” is thus prevented from rotating in relation to the delivery member guard 5”.
  • Fig. 26 shows when the lid assembly is removed from the housing 1 .
  • the tubular body 20” is shown transparent to illustrate the underlying components.
  • the tubular body 20” is rotated or turned relative to the housing 1 as shown by the arrow. This causes the tubular body 20” to disengage from the housing 1 and further to move axially in the cap removal direction due to the cooperating cam surfaces, shown by the arrow 108.
  • the inner body 30” and the tubular body 20” are engaged axially, e.g., by the fitting arm 32” and the flange 20a” while the tubular body 20” is free to rotate relative to the inner body 20”.
  • the axial movement of the tubular body 20” brings with it the inner body 30”, which is prevented from rotation due to it being rotationally locked relative to the delivery member guard 5”.
  • the inner body 30” will thus solely perform linear movement relative to the housing 1 when the delivery member shield 43 is pulled off by the one or more gripper 33”.
  • the delivery member shield 43 will thus not rotate when it is pulled off from the syringe.
  • the syringe will also not be rotated when the delivery member shield 43 is pulled off the syringe.
  • the delivery member guard may have a larger distance between its distally directed legs, which can accommodate the syringe flange in any rotational orientation.
  • Figs 27-28 show an example of a medicament delivery device of this type, with the crosssection being taken at an axial location along the medicament delivery device where the syringe has its syringe flange 41.
  • the legs 107”’ of the delivery member guard are designed to have a greater distance between them, to accommodate for rotation of the syringe flange 41 , which is rotationally non- symmetric, between the legs 107”’.
  • the cut, or planar, faces 109 of the syringe flange 41 are facing the legs 107’”.
  • Fig. 28 shows the medicament delivery device after the lid assembly has been removed by rotation, causing the syringe to rotate too as the delivery member shield is rotated with the inner body.
  • curved portions 111 now face the inner surface of the legs 107.
  • the curved portions 111 are still spaced-apart from the inner surface of the legs 107.
  • the syringe flange 41 is free to rotate within the housing 1 without striking any internal component.
  • This example may require scaling up of other components too, such as the housing 1 , for example, to accommodate the larger delivery member guard.
  • the housing of the medicament delivery device may be provided with (i.e., molded in, molded with) a compound featuring persistently antimicrobial, antifungal, and/or antiviral properties.
  • a compound featuring persistently antimicrobial, antifungal, and/or antiviral properties may be applied to the molded (i.e., finished) components through secondary processes (e.g., chemical vapor deposition), spraying, or dipping processes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Un ensemble capuchon d'un dispositif d'administration de médicament comprend une seringue avec un cylindre, une protection d'élément d'administration et un épaulement de rampe s'étendant entre le cylindre et la protection d'élément d'administration, l'ensemble capuchon comprenant : un corps tubulaire s'étendant le long d'un axe longitudinal entre une extrémité proximale et une extrémité distale ; un couvercle partiellement reçu à l'intérieur du corps tubulaire ; le couvercle comprenant un capot de couvercle s'étendant dans une direction transversale à l'axe longitudinal et un corps interne s'étendant du capot de couvercle vers l'extrémité distale du corps tubulaire ; le capot de couvercle étant fixé de manière axiale et mobile à l'extrémité proximale du corps tubulaire et étant fixé de manière inamovible au corps interne ; le corps interne comprenant une pince radialement flexible conçue pour venir en prise avec la protection d'élément d'administration de telle sorte que la protection d'élément d'administration peut être retirée de la seringue par un mouvement proximal du corps interne par rapport à la seringue ; et le couvercle étant mobile axialement par rapport au corps tubulaire dans la direction de l'axe longitudinal entre une position distale et une position proximale.
PCT/EP2024/056273 2023-03-22 2024-03-08 Ensemble capuchon d'un dispositif d'administration de médicament Pending WO2024194045A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202480013510.4A CN120731101A (zh) 2023-03-22 2024-03-08 药剂递送装置的端帽组件

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP23163518.6 2023-03-22
EP23163518 2023-03-22
US202363468335P 2023-05-23 2023-05-23
US63/468,335 2023-05-23

Publications (1)

Publication Number Publication Date
WO2024194045A1 true WO2024194045A1 (fr) 2024-09-26

Family

ID=90361474

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/056273 Pending WO2024194045A1 (fr) 2023-03-22 2024-03-08 Ensemble capuchon d'un dispositif d'administration de médicament

Country Status (2)

Country Link
CN (1) CN120731101A (fr)
WO (1) WO2024194045A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2175917B1 (fr) * 2007-08-08 2013-06-26 Cilag GmbH International Dispositif d'injection à mécanisme de verrouillage pour porte-seringue
US10512729B2 (en) * 2015-08-20 2019-12-24 Owen Mumford Limited Priming arrangement for drug delivery device
WO2020069994A1 (fr) * 2018-10-01 2020-04-09 Sanofi Capuchon
US11147932B2 (en) 2016-11-15 2021-10-19 Shl Medical Ag Medicament delivery device having a cap assembly
US20220078987A1 (en) 2016-12-06 2022-03-17 Pioneer Hi-Bred International, Inc. Sorghum maternal haploid inducing line smhi02
US20220111153A1 (en) * 2019-02-26 2022-04-14 Becton Dickinson France Rigid needle shield remover with drop test feature for autoinjector
WO2022078987A1 (fr) * 2020-10-14 2022-04-21 Shl Medical Ag Mécanisme de verrouillage pour un dispositif d'administration de médicament

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2175917B1 (fr) * 2007-08-08 2013-06-26 Cilag GmbH International Dispositif d'injection à mécanisme de verrouillage pour porte-seringue
US10512729B2 (en) * 2015-08-20 2019-12-24 Owen Mumford Limited Priming arrangement for drug delivery device
US11147932B2 (en) 2016-11-15 2021-10-19 Shl Medical Ag Medicament delivery device having a cap assembly
US20220078987A1 (en) 2016-12-06 2022-03-17 Pioneer Hi-Bred International, Inc. Sorghum maternal haploid inducing line smhi02
WO2020069994A1 (fr) * 2018-10-01 2020-04-09 Sanofi Capuchon
US20220111153A1 (en) * 2019-02-26 2022-04-14 Becton Dickinson France Rigid needle shield remover with drop test feature for autoinjector
WO2022078987A1 (fr) * 2020-10-14 2022-04-21 Shl Medical Ag Mécanisme de verrouillage pour un dispositif d'administration de médicament

Also Published As

Publication number Publication date
CN120731101A (zh) 2025-09-30

Similar Documents

Publication Publication Date Title
WO2024194045A1 (fr) Ensemble capuchon d'un dispositif d'administration de médicament
WO2025149370A1 (fr) Sous-ensemble d'un dispositif d'administration de médicament
KR20240113956A (ko) 약물 전달 장치용 서브 조립체
WO2025031781A1 (fr) Sous-ensemble d'un dispositif d'administration de médicament
WO2025195799A1 (fr) Sous-ensemble d'un dispositif d'administration de médicament
WO2024083511A1 (fr) Sous-ensemble d'un dispositif d'administration de médicament
WO2025002836A1 (fr) Ensemble capuchon d'un dispositif d'administration de médicament
WO2025163053A1 (fr) Sous-ensemble d'un dispositif de délivrance de médicament
EP4611857A1 (fr) Sous-ensemble d'un dispositif d'administration de médicament
KR20250142427A (ko) 의약 전달 디바이스
EP4633703A1 (fr) Sous-ensemble d'un dispositif d'administration de médicament
WO2024094441A1 (fr) Sous-ensemble d'un dispositif d'administration de médicament
WO2025256914A1 (fr) Sous-ensemble d'un dispositif d'administration de médicament
WO2024240512A1 (fr) Sous-ensemble d'un dispositif d'administration de médicament avec capuchon rotatif
WO2024217911A1 (fr) Mécanisme de pause pour un ensemble d'entraînement d'un dispositif d'administration de médicament
EP4622690A1 (fr) Couvercle distal d'un dispositif d'administration de médicament
WO2025233134A1 (fr) Sous-ensemble d'un dispositif d'administration de médicament
EP4665429A1 (fr) Sous-ensemble de dispositif d'administration de médicament
WO2024188691A1 (fr) Dispositif d'administration de médicament
WO2024121118A1 (fr) Sous-ensemble pour dispositif d'administration de médicament
EP4630081A1 (fr) Composant de verrouillage pour un dispositif d'administration de médicament
EP4661936A1 (fr) Sous-ensemble pour un dispositif d'administration de médicament, dispositif d'administration de médicament et procédé de fonctionnement d'un dispositif d'administration de médicament
WO2024153448A1 (fr) Dispositif d'injection pour administration d'un médicament
WO2025061618A1 (fr) Dispositif d'administration de médicament
WO2025113999A1 (fr) Dispositif d'administration de médicament

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24709127

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202480013510.4

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 202480013510.4

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2024709127

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024709127

Country of ref document: EP

Effective date: 20251022